IBDEI2FX ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,41392,1,4,0)
 ;;=4^D68.0
 ;;^UTILITY(U,$J,358.3,41392,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,41393,0)
 ;;=C88.0^^159^2004^195
 ;;^UTILITY(U,$J,358.3,41393,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41393,1,3,0)
 ;;=3^Waldenstrom Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,41393,1,4,0)
 ;;=4^C88.0
 ;;^UTILITY(U,$J,358.3,41393,2)
 ;;=^5001748
 ;;^UTILITY(U,$J,358.3,41394,0)
 ;;=C91.02^^159^2004^3
 ;;^UTILITY(U,$J,358.3,41394,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41394,1,3,0)
 ;;=3^Acute Lymphoblastic Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,41394,1,4,0)
 ;;=4^C91.02
 ;;^UTILITY(U,$J,358.3,41394,2)
 ;;=^5001764
 ;;^UTILITY(U,$J,358.3,41395,0)
 ;;=C92.02^^159^2004^6
 ;;^UTILITY(U,$J,358.3,41395,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41395,1,3,0)
 ;;=3^Acute Myeloblastic Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,41395,1,4,0)
 ;;=4^C92.02
 ;;^UTILITY(U,$J,358.3,41395,2)
 ;;=^5001791
 ;;^UTILITY(U,$J,358.3,41396,0)
 ;;=D09.3^^159^2004^45
 ;;^UTILITY(U,$J,358.3,41396,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41396,1,3,0)
 ;;=3^Carcinoma in Situ of Thyroid/Oth Endocrine Glands
 ;;^UTILITY(U,$J,358.3,41396,1,4,0)
 ;;=4^D09.3
 ;;^UTILITY(U,$J,358.3,41396,2)
 ;;=^5001955
 ;;^UTILITY(U,$J,358.3,41397,0)
 ;;=C22.0^^159^2004^86
 ;;^UTILITY(U,$J,358.3,41397,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41397,1,3,0)
 ;;=3^Hepatocellular Carcinoma
 ;;^UTILITY(U,$J,358.3,41397,1,4,0)
 ;;=4^C22.0
 ;;^UTILITY(U,$J,358.3,41397,2)
 ;;=^5000933
 ;;^UTILITY(U,$J,358.3,41398,0)
 ;;=C24.9^^159^2004^110
 ;;^UTILITY(U,$J,358.3,41398,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41398,1,3,0)
 ;;=3^Malig Neop Biliary Tract,Unspec
 ;;^UTILITY(U,$J,358.3,41398,1,4,0)
 ;;=4^C24.9
 ;;^UTILITY(U,$J,358.3,41398,2)
 ;;=^5000942
 ;;^UTILITY(U,$J,358.3,41399,0)
 ;;=C50.922^^159^2004^134
 ;;^UTILITY(U,$J,358.3,41399,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41399,1,3,0)
 ;;=3^Malig Neop Left Male Breast,Unspec Site
 ;;^UTILITY(U,$J,358.3,41399,1,4,0)
 ;;=4^C50.922
 ;;^UTILITY(U,$J,358.3,41399,2)
 ;;=^5133340
 ;;^UTILITY(U,$J,358.3,41400,0)
 ;;=C34.91^^159^2004^152
 ;;^UTILITY(U,$J,358.3,41400,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41400,1,3,0)
 ;;=3^Malig Neop Right Bronchus/Lung,Unspec Part
 ;;^UTILITY(U,$J,358.3,41400,1,4,0)
 ;;=4^C34.91
 ;;^UTILITY(U,$J,358.3,41400,2)
 ;;=^5000967
 ;;^UTILITY(U,$J,358.3,41401,0)
 ;;=C50.921^^159^2004^156
 ;;^UTILITY(U,$J,358.3,41401,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41401,1,3,0)
 ;;=3^Malig Neop Right Male Breast,Unspec Site
 ;;^UTILITY(U,$J,358.3,41401,1,4,0)
 ;;=4^C50.921
 ;;^UTILITY(U,$J,358.3,41401,2)
 ;;=^5001198
 ;;^UTILITY(U,$J,358.3,41402,0)
 ;;=C90.02^^159^2004^167
 ;;^UTILITY(U,$J,358.3,41402,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41402,1,3,0)
 ;;=3^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,41402,1,4,0)
 ;;=4^C90.02
 ;;^UTILITY(U,$J,358.3,41402,2)
 ;;=^5001753
 ;;^UTILITY(U,$J,358.3,41403,0)
 ;;=D51.9^^159^2004^25
 ;;^UTILITY(U,$J,358.3,41403,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41403,1,3,0)
 ;;=3^Anemia in Vitamin B12 Deficiency
 ;;^UTILITY(U,$J,358.3,41403,1,4,0)
 ;;=4^D51.9
 ;;^UTILITY(U,$J,358.3,41403,2)
 ;;=^5002289
 ;;^UTILITY(U,$J,358.3,41404,0)
 ;;=C79.51^^159^2004^30
 ;;^UTILITY(U,$J,358.3,41404,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41404,1,3,0)
 ;;=3^Bone Mets
 ;;^UTILITY(U,$J,358.3,41404,1,4,0)
 ;;=4^C79.51
 ;;^UTILITY(U,$J,358.3,41404,2)
 ;;=^5001350
 ;;^UTILITY(U,$J,358.3,41405,0)
 ;;=C80.1^^159^2004^163
 ;;^UTILITY(U,$J,358.3,41405,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41405,1,3,0)
 ;;=3^Malig Neop,Primary,Unspec Site
